HongKong:1916701D

The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar

Retrieved on: 
星期三, 二月 15, 2023

SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.

Key Points: 
  • SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.
  • https://novotech-cro.com/whitepapers/vaccines-asia-pacific-clinical-tria...
    The webinar, Keeping pace with the evolving global landscape in vaccine development, will hear from a panel of life science experts on the latest advancements and innovative modalities paving the way in the global vaccine development space including:
    - The COVID-19 impact on drug development and the regulatory landscape.
  • - Key factors contributing to Asia Pacific being recognised as the hub for vaccine development and opportunities for biotech's to leverage.
  • - Key considerations for pre-clinical and clinical planning to accelerate vaccine development, supporting a robust global strategy.

Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific

Retrieved on: 
星期五, 二月 10, 2023

SYDNEY, AU, Feb 10, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO, has published a new global report on Phase 1 trial activity including current metrics on fast growth regions and therapeutic areas.

Key Points: 
  • SYDNEY, AU, Feb 10, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO, has published a new global report on Phase 1 trial activity including current metrics on fast growth regions and therapeutic areas.
  • According to the report, titled "Phase I Global Clinical Trial Landscape - Focus on Asia Pacific", in 2022 Asia Pacific accounted for a 58% share of the approximately 3,600 Phase I trials initiated globally in 2022.
  • The report found that Asia Pacific also leads phase I trials across the top therapeutic areas.
  • View "Phase I Global Clinical Trial Landscape - Focus on Asia Pacific", the new report, on this link: https://tinyurl.com/novotech-global-report
    See the report for Phase 1 location and therapeutic area analysis including: